|
Dr. Harry Mansbach leads the company's clinical and pre-clinical operations, pharmaceutical development and line extension development for retigabine, taribavirin, Diastat AcuDial and Cesamet. Before joining Valeant, Dr. Mansbach was Chief Medical Officer and Vice President, Clinical Development at Cortex Pharmaceuticals in Irvine, Calif., an emerging biotech company specializing in central nervous system (CNS) therapeutics. Prior to his position at Cortex, he worked at GlaxoSmithKline in Research Triangle Park, N.C. Dr. Mansbach has been involved with the development and -management of a number of significant CNS products and is experienced in all phases of drug development from pre-clinical testing through Phase 4. Dr. Mansbach finished his neurology residency at the University of Michigan Health System and completed subspecialty fellowship training in cerebrovascular diseases at the Henry Ford Hospital in Detroit, Michigan. He is Board certified in neurology and was a member of the Department of Neurology senior staff in the Henry Ford Health System. He earned his Bachelor's degree from Yale University and his M.D. degree from the Duke University School of Medicine | 